hepatitis c

ACSH friend, Dr. Robert Popovian, the Senior Director of Healthcare, Science and Economic Advocacy and U.S. Government Relations at Pfizer, is arguably one of the world s premier experts in all aspects of the industry, from early stage discovery to development, as well as innovation, economics, and government policy.
A new report by IMS Health, a consulting company that provides information and analyses of multiple facets of healthcare economic, scientific, others concluded that prescription drug costs jumped by more than 13 percent last year the biggest increase since 2001.
It is rare when a single drug entirely revolutionizes the treatment of a disease. Yet, Gilead s Sovaldi did just this, following its FDA approval in late 2013.
Dr. Josh Bloom and Dr. Henry I. Miller in Forbes.com, January 14, 2015 The development of pharmaceuticals is among the riskiest of businesses. It now takes 10-15 years for a pharmaceutical company to get a new drug approved, and on average the cost exceeds $2.5 billion. To establish its safety and effectiveness, a candidate drug or vaccine undergoes a lengthy process of laboratory,...[Read more].
Catch the latest news on concerns regarding Gilead's $84,000 hepatitis C treatment drug Sovaldi, the declining sales of traditional cigarettes, and why prior authorization could be hurting the health care system
There are now multiple ongoing discussions about Sovaldi, Gilead s revolutionary drug for treating hepatitis C. The arguments are more or less
Seems like old times: a few expensive new drugs (although money-saving in the long-term) lead to renewed calls for negotiated prices for Medicare patients price controls. Short-term savings are short-sighted however: politicians think long-term is the next election.
In what was was either a freak accident or someone actually using their mind, The Centers for Medicare & Medicaid Services
Get the latest news on the costly Hepatitis C drug, why C-sections have skyrocketed in numbers, and the real reason behind the lack of research on antibiotic research
As we discussed here two months ago, Gilead s Sovaldi a revolutionary treatment that can actually cure hepatitis C was under attack for its cost ($1000 per daily pill for 12 weeks, or $84,000).
In the no good deed goes unpunished department, California s Gilead Sciences has come under attack by Congressman Henry Waxman a perennial critic of the drug industry. In this case, the issue is the price of Gilead s Sovaldi one of the most revolutionary new drugs to come along in some time.
It would be almost impossible to find a better example of the difficulties that face the pharmaceutical industry than the campaign against hepatitis C. Called The Silent Killer, the blood-borne disease infects the liver, gradually doing irreversible damage over a two- to three-decade period. Most people who are infected do not even know this until symptoms of liver failure show up, at which time the disease can be life threatening. The majority of liver transplants in the U.S. are due to liver failure caused by long-term hepatitis C infection.